文献速递临床试验与 GCP基础与转化研究

晚肝期减毒疟原虫免疫接种的安全性与效力

Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria Parasite.
PubMed 文献 · N Engl J Med · 2024-01-01

这项双盲对照临床试验评估了经蚊虫叮咬接种第二代基因减毒疟原虫(GA2)的安全性、不良反应谱和效力。在开放标签剂量递增安全性阶段后,健康成人随机接受GA2、早期阻滞疟原虫(GA1)或安慰剂免疫各3次(每次50只蚊叮咬)。控制性人疟感染后,GA2组9人中8人(89%)获得保护,GA1组8人中1人(13%),安慰剂组3人中0人。

要点

  • GA2组保护效力为8/9(89%),GA1组为1/8(13%),安慰剂组为0/3。
  • GA2组疟原虫特异性多功能CD4+和Vδ2+ γδ T细胞频率显著高于GA1组。
  • GA2与GA1诱导的针对环子孢子蛋白的抗体滴度相似。

核心结论

  • 在这项小型试验中,GA2与良好的免疫诱导特征和保护效力相关,这些发现值得进一步评估。

研究设计与样本

  • 双盲、对照临床试验,评估经蚊虫叮咬接种第二代基因减毒疟原虫(GA2,mei2单敲除恶性疟原虫NF54株子孢子,肝期发育延长)的安全性、不良反应谱和效力。
  • A阶段为开放标签剂量递增安全性阶段,参与者暴露于15或50只感染蚊虫叮咬。
  • B阶段将未患过疟疾的健康成人随机分配至每次免疫接受50只GA2感染蚊叮咬、早期阻滞疟原虫(GA1)或安慰剂(未感染蚊叮咬)组。
  • 完成三次免疫(每次50只蚊叮咬)后,比较GA2、GA1和安慰剂对同源恶行疟原虫控制性人疟感染的保护效力。

主要发现

  • 不良事件在各试验组间相似。
  • 对 subsequent 控制性人疟感染的保护效力:GA2组9人中8人(89%),GA1组8人中1人(13%),安慰剂组3人中0人。
  • 接受GA2的参与者中疟原虫特异性多功能CD4+和Vδ2+ γδ T细胞频率显著高于接受GA1者。
  • GA2和GA1诱导的针对恶行疟原虫环子孢子蛋白的抗体滴度相似。

关键数值与推荐

  • 主要终点为A阶段和B阶段不良事件的数量和严重程度,以及A阶段GA2感染蚊叮咬后和B阶段控制性人疟感染后每毫升血液中恶行疟原虫超过100个的血期寄生虫血症。

局限性

  • 在这项小型试验中,GA2与良好的免疫诱导特征和保护效力相关,这些发现值得进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Currently licensed and approved malaria subunit vaccines provide modest, short-lived protection against malaria. Immunization with live-attenuated Plasmodium falciparum malaria parasites is an alternative vaccination strategy that has potential to improve protection. METHODS: We conducted a double-blind, controlled clinical trial to evaluate the safety, side-effect profile, and efficacy of immunization, by means of mosquito bites, with a second-generation genetically attenuated parasite (GA2) - a mei2 single knockout P. falciparum NF54 parasite (sporozoite form) with extended development into the liver stage. After an open-label dose-escalation safety phase in which participants were exposed to the bites of 15 or 50 infected mosquitoes (stage A), healthy adults who had not had malaria were randomly assigned to be exposed to 50 mosquito bites per immunization of GA2, an early-arresting parasite (GA1), or placebo (bites from uninfected mosquitoes) (stage B). After the completion of three immunization sessions with 50 mosquito bites per session, we compared the protective efficacy of GA2 against homologous P. falciparum controlled human malaria infection with that of GA1 and placebo. The primary end points were the number and severity of adverse events (in stages A and B) and blood-stage parasitemia greater than 100 P. falciparum parasites per milliliter after bites from GA2-infected mosquitoes (in stage A) and after controlled human malaria infection (in stage B). RESULTS: Adverse events were similar across the trial groups. Protective efficacy against subsequent controlled human malaria infection was observed in 8 of 9 participants (89%) in the GA2 group, in 1 of 8 participants (13%) in the GA1 group, and in 0 of 3 participants in the placebo group. A significantly higher frequency of P. falciparum-specific polyfunctional CD4+ and Vδ2+ γδ T cells were observed among participants who received GA2 than among those who received GA1, whereas GA2 and GA1 induced similar antibody titers targeting the P. falciparum circumsporozoite protein. CONCLUSIONS: In this small trial, GA2 was associated with a favorable immune induction profile and protective efficacy, findings that warrant further evaluation. (Funded by the Bontius Foundation; ClinicalTrials.gov number, NCT04577066.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Lamers OAC, Franke-Fayard BMD, Koopman JPR, et al. Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria Parasite. N Engl J Med. 2024. PMID: 39565990. doi:10.1056/NEJMoa2313892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。